Autologous stem cell transplantation in myeloma: the St James’s Hospital experience, 1997–2003

  • P. J. Hayden
  • A. O’Driscoll
  • N. Gardiner
  • R. Swords
  • J. Sargent
  • F. Ni Ainle
  • A. Fortune
  • P. T. Murphy
  • M. Leahy
  • F. Jackson
  • M. Ryan
  • B. Hennessy
  • M. Cahill
  • G. M. Crotty
  • H. Enright
  • E. Conneally
  • E. Vandenberghe
  • S. R. McCann
  • P. V. Browne
Original Papers

Abstract

Background

High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years.

Aims

We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James’s Hospital in Dublin between 1997 and 2003 inclusive.

Methods

Clinical and laboratory data were retrieved from patient medical records and hospital information management systems.

Results

Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n = 54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively.

Conclusion

Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.

References

  1. 1.
    Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology.Biomed Pharmacother 2002; 56(5): 223–34.CrossRefPubMedGoogle Scholar
  2. 2.
    MRC Working party on Leukaemia in Adults. Report on the second myelomatosis trial after 5 years of follow-up.Br J Cancer 1980; 42: 813–22.Google Scholar
  3. 3.
    Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus Melphalan and Prednisolone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomised trials.J Clin Oncol 1998: 16: 3832–42.Google Scholar
  4. 4.
    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma.Lancet 1983; 2: 822–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.Blood 1986; 67: 1298–301.PubMedGoogle Scholar
  6. 6.
    Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.N Engt Med 1996; 335:91–7.CrossRefGoogle Scholar
  7. 7.
    Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood. 1999 Jan 1; 93(1): 55–65.PubMedGoogle Scholar
  8. 8.
    Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.N Engl J Med. 2003 May 8; 348(19): 1875–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Barlogie B, Shaughnessey J, Tricot G et al. Treatment of multiple myeloma.Blood 2004; 103: 20–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Blade J. High-dose therapy in multiple myeloma.Blood 2003; 102: 3469–3477.CrossRefPubMedGoogle Scholar
  11. 11.
    Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.Br J Haematol 1998; 102: 1115–1123.CrossRefPubMedGoogle Scholar
  12. 12.
    Tha UK Myeloma Forum Guideline: Diagnosis and Management of multiple myeloma.Br J Haematol 2001; 115: 522–540.CrossRefGoogle Scholar
  13. 13.
    Durie BGM, Kyle RA, Belch A et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.The Haematol J 2003; 4: 379–398.Google Scholar
  14. 14.
    Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.Br J Haematol 2001; 114: 600–607.CrossRefPubMedGoogle Scholar
  15. 15.
    Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple Myeloma: identification of favourable variablesfor rapid engraftment in 225 patients.Blood 1995; 85: 588–96.PubMedGoogle Scholar
  16. 16.
    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma.Am J Hematol. 1990 Feb; 33(2): 86–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Cook G, Sharp RA, Tansey P et al. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma.Br J Haematol 1996; 93: 931–934.CrossRefPubMedGoogle Scholar
  18. 18.
    Anagnostopoulos A, Aleman A, Yang Y et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasonebased nonmyelosuppressive induction therapy.Bone Marrow Transplant 2004 Mar; 33(6): 623–628.CrossRefPubMedGoogle Scholar
  19. 19.
    Kumar, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. 2004 May 10 (epub ahead of print).Google Scholar
  20. 20.
    Cottler-Fox MH, Lapidot T, Petit I et al. Stem Cell Mobilization. ASH Education Book:Hematology 2003: 419–437.Google Scholar
  21. 21.
    Vescio R, Schiller G, Steward AK et al. Multicenter phase III trial to evaluate CD34 (+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple Myeloma.Blood 1999; 93: 1858–68.PubMedGoogle Scholar
  22. 22.
    Steward AK, Vescio R, Schiller G et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicentre randomised controlled trial.J Clin Oncol 2001; 19: 3771–9.Google Scholar
  23. 23.
    Siegel D, Mehta J, Anaissie E et al. Prolonged immunosuppression after CD34+ or CD34+/Thy-1+/ Linselected autologous peripheral blood stem cell (PBSC) transplants. (Tx) for multiple myeloma. Blood 1997: 90 (Suppl 1): 112a.Google Scholar
  24. 24.
    Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous haematopoietic stemcell infusion for patients with multiple myeloma.J Clin Oncol 1996; 14: 1447–56.PubMedGoogle Scholar
  25. 25.
    Moreau P, Facon T, Attal M et al. Comparison of 200 mg/ m (2) melphalan and 8 Gy total body irradiation plus 140 mg/m (2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomised trial.Blood 2002 Feb 1; 99(3): 731–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.Br J Haematol 2001; 114: 822–829.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee CK, Zangari M, Barlogie B et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.Bone Marrow Transplant. 2004 Apr; 33(8): 823–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Terpos E, Apperley JF, Samson D et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single centre experience in 127 patients.Bone Marrow Transplant 2003; 31: 163–170.CrossRefPubMedGoogle Scholar
  29. 29.
    Nadal E, Gine E, Blade J et al. High-dose therapy/ autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.Bone Marrow Transplant 2003; 33: 61–64.CrossRefGoogle Scholar
  30. 30.
    Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, doubleblind, multicenter, comparative trial.Cancer. 2003 Oct 15; 98(8): 1735–44.CrossRefPubMedGoogle Scholar
  31. 31.
    Alegre A, Granda A, Martinez-Chamarro C et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish registry.Haematologica 2002; 87:609–614.PubMedGoogle Scholar
  32. 32.
    Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple Myeloma.N Engl J Med 1999; 341: 1565–71.CrossRefPubMedGoogle Scholar
  33. 33.
    Catley L and Anderson K. Strategies to improve the outcome of stem cell transplantation in multiple myeloma.The Haematol J 2004; 5: 9–23.Google Scholar
  34. 34.
    Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple Myeloma: a population-based study.Blood 2000; 95: 7–11.PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • P. J. Hayden
    • 1
  • A. O’Driscoll
    • 1
  • N. Gardiner
    • 1
  • R. Swords
    • 2
  • J. Sargent
    • 3
  • F. Ni Ainle
    • 4
  • A. Fortune
    • 5
  • P. T. Murphy
    • 2
  • M. Leahy
    • 3
  • F. Jackson
    • 4
  • M. Ryan
    • 4
  • B. Hennessy
    • 6
  • M. Cahill
    • 7
  • G. M. Crotty
    • 8
  • H. Enright
    • 5
  • E. Conneally
    • 1
  • E. Vandenberghe
    • 1
  • S. R. McCann
    • 1
  • P. V. Browne
    • 1
  1. 1.Dept. of HaematologySt James’s HospitalDublin 8
  2. 2.Dept of HaematologyBeaumont HospitalDublin 9
  3. 3.Dept. of HaematologyMid-West Regional HospitalCo. Limerick
  4. 4.Dept. of HaematologyWaterford Regional HospitalCo. Waterford
  5. 5.Dept. of HaematologyAMNCHDublin 24
  6. 6.Dept. of HaematologyLetterkenny General HospitalCo. Donegal
  7. 7.Dept. of HaematologyCork University HospitalCork
  8. 8.Dept. of HaematologyMidland Regional HospitalCo. Offaly
  9. 9.Dept. of HaematologySt. James’s HospitalDublin 8Ireland

Personalised recommendations